Oblique Therauptics

Oblique Therapeutics  is a leading biotechnology company that focuses on developing new therapeutic methods for treating severe illnesses, especially in the area of pain management and also for other conditions. The company uses pioneering technology and innovative research methods to discover and develop new drug candidates.

Oblique Therapeutics is collaborating with the KTH Royal Institute of Technology to utilise state-of-the-art supercomputer resources at PDC for analysing protein structures. This partnership aims to accelerate research and development in the area of innovative treatments for various illnesses. The PDC computing and storage resources will give Oblique Therapeutics an unsurpassed capacity to process and analyse large quantities of data, which is vital for understanding the development of protein structures and their biochemical properties. By combining Oblique Therapeutics’ expertise in drug development research with KTH’s advanced technological resources, it is expected that this collaboration will lead to significant progress in biomedical R&D. The collaboration will focus on accelerating the development of therapeutic antibodies for some of the most important target proteins related to neurological illnesses, including chronic pain, migraine and more.

For questions about this or other PDC business partnerships, please contact business-unit@pdc.kth.se .